Total Payments
$753,174
2024 Payments
$32,106
Companies
15
Transactions
84
Medicare Patients
1,242
Medicare Billing
$75,799
Payment Breakdown by Category
Research$742,159 (98.5%)
Consulting$6,155 (0.8%)
Travel$2,797 (0.4%)
Food & Beverage$2,063 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $742,159 | 41 | 98.5% |
| Consulting Fee | $6,155 | 4 | 0.8% |
| Travel and Lodging | $2,797 | 13 | 0.4% |
| Food and Beverage | $2,063 | 26 | 0.3% |
Payments by Type
Research
$742,159
41 transactions
General
$11,014
43 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sebela Pharmaceuticals Inc. | $491,938 | 24 | $0 (2020) |
| Exeltis, USA Inc. | $155,410 | 2 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $55,050 | 9 | $0 (2024) |
| Gen-Probe, Inc. | $36,568 | 2 | $0 (2019) |
| Mitsubishi Tanabe Pharma Development America, Inc. | $4,142 | 14 | $0 (2017) |
| AbbVie, Inc. | $3,794 | 11 | $0 (2019) |
| Myovant Sciences Inc. | $3,130 | 2 | $0 (2021) |
| Allergan Inc. | $1,335 | 4 | $0 (2017) |
| Medicines360 | $798.91 | 6 | $0 (2018) |
| AMAG Pharmaceuticals, Inc. | $469.55 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,106 | 7 | Teva Pharmaceuticals USA, Inc. ($31,910) |
| 2023 | $23,420 | 6 | Teva Pharmaceuticals USA, Inc. ($23,140) |
| 2021 | $3,130 | 2 | Myovant Sciences Inc. ($3,130) |
| 2020 | $299,323 | 13 | Exeltis, USA Inc. ($155,268) |
| 2019 | $384,587 | 16 | Sebela Pharmaceuticals Inc. ($347,884) |
| 2018 | $4,822 | 18 | AbbVie, Inc. ($3,780) |
| 2017 | $5,786 | 22 | Mitsubishi Tanabe Pharma Development America, Inc. ($4,142) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Hologic Sales and Service, LLC | APTIMA (Device) | Food and Beverage | In-kind items and services | $81.12 | General |
| Category: Diagnostics | ||||||
| 07/05/2024 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $9,800.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 05/23/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $115.18 | General |
| Category: Biological | ||||||
| 04/16/2024 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $4,200.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 03/29/2024 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $4,900.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 03/02/2024 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $7,250.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 01/18/2024 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $5,760.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 12/29/2023 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $1,440.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 12/07/2023 | Hologic Sales and Service, LLC | APTIMA (Device) | Food and Beverage | In-kind items and services | $138.15 | General |
| Category: Diagnostics | ||||||
| 10/17/2023 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $4,320.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 10/10/2023 | Exeltis, USA Inc. | SLYND (Drug) | Food and Beverage | In-kind items and services | $141.81 | General |
| Category: Oral Contraceptive | ||||||
| 08/18/2023 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $8,880.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 01/04/2023 | Teva Pharmaceuticals USA, Inc. | ESTRADIOL (Drug) | — | Cash or cash equivalent | $8,500.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy • Category: Women's Health | ||||||
| 07/07/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 02/17/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Consulting Fee | Cash or cash equivalent | $130.00 | General |
| Category: HORMONE THERAPY | ||||||
| 12/31/2020 | Exeltis, USA Inc. | LPRI-424 (Drug) | — | Cash or cash equivalent | $155,268.20 | Research |
| Study: A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles • Category: Oral Contraceptive | ||||||
| 11/13/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $10,390.40 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 10/16/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $6,701.40 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 09/18/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $10,987.10 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 08/21/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $16,636.20 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 07/14/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $11,352.60 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 07/02/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $15,000.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 06/18/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,867.40 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $7,534.40 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/14/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $10,772.90 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability | Sebela Pharmaceuticals Inc. | $347,884 | 12 |
| A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles | Exeltis, USA Inc. | $155,268 | 1 |
| A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | Sebela Pharmaceuticals Inc. | $144,055 | 12 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy | Teva Pharmaceuticals USA, Inc. | $55,050 | 9 |
| A10924-VAGPS-CSP-01 | Gen-Probe, Inc. | $36,568 | 2 |
| A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women | Mitsubishi Tanabe Pharma Development America, Inc. | $2,000 | 1 |
| A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF THREE DOSES OF ESTRADIOL VAGINAL CAPSULE IN POSTMENOPAUSAL WOMEN WITH VULVOVAGINAL ATROPHY | Allergan Inc. | $885.00 | 2 |
| A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ULIPRISTAL ACETATE FOR THE INTERMITTENT TREATMENT OF ABNORMAL UTERINE BLEEDING ASSOCIATED WITH LEIOMYOMAS | Allergan Inc. | $450.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 300 | 354 | $40,050 | $17,756 |
| 2022 | 5 | 309 | 370 | $43,910 | $19,691 |
| 2021 | 6 | 359 | 440 | $50,270 | $22,946 |
| 2020 | 4 | 274 | 326 | $35,730 | $15,407 |
Total Patients
1,242
Total Services
1,490
Medicare Billing
$75,799
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 151 | 194 | $28,130 | $11,535 | 41.0% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2023 | 82 | 82 | $3,690 | $3,205 | 86.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 30 | 30 | $6,150 | $2,310 | 37.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 17 | $1,615 | $637.59 | 39.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 25 | 31 | $465.00 | $68.20 | 14.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 150 | 207 | $30,015 | $12,575 | 41.9% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2022 | 81 | 81 | $3,645 | $3,289 | 90.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 32 | 32 | $6,560 | $2,613 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 14 | $3,150 | $1,134 | 36.0% |
| 81003 | Automated urinalysis test | Office | 2022 | 32 | 36 | $540.00 | $79.87 | 14.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 163 | 237 | $34,365 | $14,592 | 42.5% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2021 | 90 | 90 | $4,050 | $3,653 | 90.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 38 | 38 | $7,790 | $3,268 | 41.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 14 | $3,150 | $1,253 | 39.8% |
| 81003 | Automated urinalysis test | Office | 2021 | 42 | 49 | $735.00 | $110.25 | 15.0% |
| 87210 | Smear for infectious agents | Office | 2021 | 12 | 12 | $180.00 | $69.84 | 38.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 144 | 191 | $25,655 | $9,674 | 37.7% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2020 | 79 | 79 | $3,555 | $3,239 | 91.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 31 | 31 | $6,145 | $2,437 | 39.7% |
| 81003 | Automated urinalysis test | Office | 2020 | 20 | 25 | $375.00 | $56.00 | 14.9% |
About Dr. Rex Mabey, M.D
Dr. Rex Mabey, M.D is a Obstetrics & Gynecology healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720048549.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rex Mabey, M.D has received a total of $753,174 in payments from pharmaceutical and medical device companies, with $32,106 received in 2024. These payments were reported across 84 transactions from 15 companies. The most common payment nature is "" ($742,159).
As a Medicare-enrolled provider, Mabey has provided services to 1,242 Medicare beneficiaries, totaling 1,490 services with total Medicare billing of $75,799. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Location Las Vegas, NV
- Active Since 03/24/2006
- Last Updated 03/08/2011
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1720048549
Products in Payments
- LPRI-424 (Drug) $155,268
- ESTRADIOL (Drug) $55,050
- Aptima Trichomonas (Device) $36,568
- ESTRACE CREAM (Drug) $885.00
- Liletta (Device) $798.91
- INTRAROSA (Drug) $469.55
- APTIMA (Device) $219.27
- SLYND (Drug) $141.81
- ORGOVYX (Drug) $130.00
- Veozah (Drug) $115.18
- ADDYI (Drug) $96.85
- Saxenda (Drug) $90.40
- DIVIGEL (Drug) $16.07
- Orilissa (Drug) $13.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Las Vegas
Dr. Darin Swainston, M.d, M.D
Obstetrics & Gynecology — Payments: $733,281
Obstetrics & Gynecology $733,281
Christina Kushnir, M.d, M.D
Obstetrics & Gynecology — Payments: $488,611
Obstetrics & Gynecology $488,611
Dr. Navkaran Singh, M.d, M.D
Obstetrics & Gynecology — Payments: $233,952
Obstetrics & Gynecology $233,952
Dr. Lamarr Tyler, D.o, D.O
Obstetrics & Gynecology — Payments: $149,318
Obstetrics & Gynecology $149,318
Ralph Vennart, Md, MD
Obstetrics & Gynecology — Payments: $120,267
Obstetrics & Gynecology $120,267
Sunwook Kim, Md, MD
Obstetrics & Gynecology — Payments: $80,840
Obstetrics & Gynecology $80,840